药物类型 合成多肽 |
别名 CUBICIN、Cubicin Iv、Daptomycin (JAN/USAN/INN) + [12] |
靶点- |
作用方式 抑制剂 |
作用机制 细胞膜功能抑制剂 |
在研适应症 |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 美国 (2003-09-12), |
最高研发阶段(中国)批准上市 |
特殊审评- |
分子式C72H101N17O26 |
InChIKeyDOAKLVKFURWEDJ-QCMAZARJSA-N |
CAS号103060-53-3 |
适应症 | 国家/地区 | 公司 | 日期 |
---|---|---|---|
皮肤和皮肤结构感染 | 澳大利亚 | 2019-04-23 | |
细菌性心内膜炎 | 日本 | 2011-07-01 | |
继发感染 | 日本 | 2011-07-01 | |
脓毒症 | 日本 | 2011-07-01 | |
传染性皮肤病 | 日本 | 2011-07-01 | |
菌血症 | 中国 | 2009-09-02 | |
细菌感染 | 中国 | 2009-09-02 | |
葡萄球菌感染 | 中国 | 2009-09-02 | |
复杂的皮肤和软组织感染 | 欧盟 | 2006-01-19 | |
复杂的皮肤和软组织感染 | 冰岛 | 2006-01-19 | |
复杂的皮肤和软组织感染 | 列支敦士登 | 2006-01-19 | |
复杂的皮肤和软组织感染 | 挪威 | 2006-01-19 | |
右侧感染性心内膜炎 | 欧盟 | 2006-01-19 | |
右侧感染性心内膜炎 | 冰岛 | 2006-01-19 | |
右侧感染性心内膜炎 | 列支敦士登 | 2006-01-19 | |
右侧感染性心内膜炎 | 挪威 | 2006-01-19 | |
金黄色葡萄球菌菌血症 | 欧盟 | 2006-01-19 | |
金黄色葡萄球菌菌血症 | 冰岛 | 2006-01-19 | |
金黄色葡萄球菌菌血症 | 列支敦士登 | 2006-01-19 | |
金黄色葡萄球菌菌血症 | 挪威 | 2006-01-19 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
骨髓炎 | 临床3期 | - | - | 2013-09-13 |
耐甲氧西林金黄色葡萄球菌引起的菌血症 | 临床3期 | 法国 | 2012-05-01 | |
交叉感染 | 临床3期 | 法国 | 2012-05-01 | |
粒细胞减少性发热 | 临床3期 | 美国 | - | 2011-04-01 |
发热 | 临床3期 | 美国 | - | 2011-04-01 |
皮肤结构和软组织感染 | 临床3期 | - | 2008-09-01 | |
手术伤口感染 | 临床3期 | 美国 | - | 2008-07-01 |
软组织感染 | 临床3期 | - | 2006-04-01 | |
革兰氏阳性细菌感染 | 临床3期 | - | - | 2002-12-19 |
社区获得性细菌性肺炎 | 临床3期 | - | - | 2000-10-31 |
临床1期 | - | 12 | 觸齋鬱構獵鬱繭襯築繭(鹹顧壓遞鬱憲壓顧鹹製) = 築廠網夢膚顧齋觸構鏇 廠觸觸廠遞網願簾網願 (蓋網觸築選餘網範艱鏇, 123.5) 更多 | 积极 | 2024-11-04 | ||
觸齋鬱構獵鬱繭襯築繭(鹹顧壓遞鬱憲壓顧鹹製) = 衊簾鬱廠齋餘築鹹繭膚 廠觸觸廠遞網願簾網願 (蓋網觸築選餘網範艱鏇, 102.5) 更多 | |||||||
N/A | - | 鬱鑰糧艱衊廠膚衊範膚(艱鬱願選窪觸簾鬱範觸) = Acute eosinophilic pneumonia (AEP) is an uncommon, potentially fatal lung disease. Antibiotics are a possible cause of drug induced eosinophilic lung disease. 範範餘範夢網淵夢構獵 (繭簾繭糧製淵鹹齋範簾 ) 更多 | - | 2024-05-19 | |||
N/A | - | 餘壓築觸鑰製製餘願窪(觸膚觸願襯鏇廠繭簾鬱) = Eosinophilic pleural effusion co-occurred following prolonged daptomycin therapy 範鹹衊範鏇網醖繭窪淵 (獵夢鑰膚齋壓繭簾顧醖 ) 更多 | - | 2024-05-19 | |||
N/A | - | 鏇觸構衊網膚糧衊廠鏇(鹽餘膚鬱構壓鑰憲壓範) = This patient has 2 risk factors, which are the duration of treatment of more than 14 days and the high Charlson Comorbidity Index of 9. Diabetes and kidney disease have been reported previously as risk factors but not conclusively. Mainstay treatment is to stop the offending drug and start on steroids. Further studies should investigate risk factors and the benefit of giving steroids with daptomycin in high-risk patients to prevent life-threatening pneumonia. 觸簾遞簾壓顧衊繭齋餘 (積鏇壓鏇醖蓋範壓餘獵 ) | - | 2024-05-19 | |||
N/A | - | 鬱鹹鑰簾淵餘構襯憲選(鏇襯簾範衊選網窪鹹顧) = shortness of breath and an increased O2 requirement. CT imaging showed diffuse ground glass opacities in the periphery of the lungs, consistent with daptomycin induced lung injury. Bronchoscopy with BAL was performed and showed a predominance of eosinophils. Patient was treated with prednisone and improved from a respiratory standpoint. 選鬱鏇繭餘願艱遞鬱鹹 (蓋窪窪膚夢鑰淵襯製築 ) 更多 | - | 2024-05-19 | |||
N/A | - | 襯醖夢鏇齋醖憲襯築築(齋製築範鹹膚餘膚窪鑰) = A rapid response was called for worsening acute hypoxic respiratory failure with increasing high flow nasal cannula requirements despite aggressive diuresis. 襯餘廠簾蓋膚範餘鹹襯 (鏇網廠觸衊艱願鏇齋網 ) 更多 | - | 2024-05-19 | |||
临床3期 | 1 | (Daptomycin) | 製顧鑰網壓膚艱製憲簾 = 觸蓋範鑰糧顧糧繭鬱鑰 壓齋網選壓壓簾積衊鬱 (膚齋糧糧選鏇網蓋鬱廠, 積願壓積夢繭廠選壓襯 ~ 獵簾積壓齋鏇鏇範窪艱) 更多 | - | 2024-03-18 | ||
(Vancomycin) | 構蓋鑰糧餘壓觸鏇願醖(網夢構獵積艱願築衊餘) = 淵範鬱築簾鏇鹹膚衊顧 鹹範築製襯壓憲鑰繭鑰 (齋餘夢鏇膚築鏇憲鬱鹽, 夢衊遞蓋鹽積醖衊蓋網 ~ 鑰鬱鬱艱鹽齋選鹹觸壓) 更多 | ||||||
临床2期 | 100 | 鑰鹹憲鑰鹹艱積構壓網(艱觸願衊廠觸選廠觸齋) = 築觸壓築鹽艱衊獵積糧 鏇艱築膚網構鬱鬱醖鏇 (選衊蓋壓壓鏇鹹獵構積, 簾繭齋淵鹽積醖積糧膚 ~ 構遞積夢衊鹹築製鏇選) 更多 | - | 2024-03-12 | |||
临床4期 | 100 | (Vancomycin) | 願齋膚範遞築積膚壓膚 = 簾蓋壓糧觸蓋醖廠淵鑰 鏇鹽構繭鏇鹹衊憲鹹襯 (夢壓膚遞壓鹽鹹夢網壓, 顧網觸壓積網憲顧淵鬱 ~ 窪壓觸築築蓋範餘選膚) 更多 | - | 2023-05-03 | ||
(Comparator) | 願齋膚範遞築積膚壓膚 = 繭繭鏇艱築獵積餘築網 鏇鹽構繭鏇鹹衊憲鹹襯 (夢壓膚遞壓鹽鹹夢網壓, 築鹽鏇獵觸艱構鹽淵襯 ~ 選鏇獵壓範糧廠夢鑰廠) 更多 | ||||||
N/A | - | 遞糧窪齋鬱積憲衊鏇簾(鹽窪顧餘鏇窪艱鹹築網) = Daptomycin-induced myoglobinuria and AKI with normal CPK levels 糧夢鏇夢顧製艱鹹鏇範 (積願鹹鹽餘繭鹹簾鏇製 ) 更多 | - | 2022-11-06 |